Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07INV
|
|||
| Former ID |
DAP000598
|
|||
| Drug Name |
Ethoxzolamide
|
|||
| Synonyms |
ethoxzolamide; Ethoxyzolamide; Ethoxazolamide; Ethamide; Etoxzolamide; Cardrase; 6-Ethoxy-2-benzothiazolesulfonamide; 452-35-7; Glaucotensil; Diuretic C; 6-Ethoxy-1,3-benzothiazole-2-sulfonamide; Mingoral; 2-Benzothiazolesulfonamide, 6-ethoxy-; Redupresin; 6-Ethoxybenzo[d]thiazole-2-sulfonamide; 6-Ethoxyzolamide; 6-Ethoxybenzothiazole-2-sulfonamide; 6-Ethoxybenzothiazole-2-sulphonamide; U-4191; NSC 10679; UNII-Z52H4811WX; C9H10N2O3S2; HSDB 3268; CHEMBL18; EINECS 207-199-5; BRN 0212240; MLS000028637; AI3-50805; Cardrase; EZL; Cardrase (TN); Ethoxzolamide (EZA); 6-(ethyloxy)-1,3-benzothiazole-2-sulfonamide; 6-Ethoxy-benzothiazole-2-sulfonic acid amide; 6-ethoxy-1,3-benzothiazole-2-sulfonamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Glaucoma/ocular hypertension [ICD-11: 9C61] | Approved | [1], [2] | |
| Duodenal ulcer [ICD-11: DA63] | Withdrawn from market | [3] | ||
| Therapeutic Class |
Diuretics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C9H10N2O3S2
|
|||
| Canonical SMILES |
CCOC1=CC2=C(C=C1)N=C(S2)S(=O)(=O)N
|
|||
| InChI |
1S/C9H10N2O3S2/c1-2-14-6-3-4-7-8(5-6)15-9(11-7)16(10,12)13/h3-5H,2H2,1H3,(H2,10,12,13)
|
|||
| InChIKey |
OUZWUKMCLIBBOG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 452-35-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
75836, 840267, 855751, 893338, 5242023, 7849499, 8152095, 10523205, 15213608, 24860121, 29215007, 29222433, 46509023, 46511452, 48415980, 49681475, 49890761, 50100966, 56422188, 57280084, 57280086, 57288316, 57304388, 57321712, 80657483, 85176911, 85306595, 87557627, 92308013, 92308213, 92729651, 95614375, 96021935, 99444198, 103048393, 103164710, 104171380, 104303092, 124587685, 124800633, 124883557, 124883558, 124897844, 125637519, 126671832, 128865742, 134337889, 134975323, 135378086, 137004941
|
|||
| ChEBI ID |
CHEBI:101096
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Eubacterium rectale ATCC 33656
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ethoxzolamide can be metabolized by Eubacterium rectale ATCC 33656 (log2FC = -0.557; p = 0.016). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Carbonic anhydrase I (CA-I) | Target Info | Modulator | [5] |
| Carbonic anhydrase II (CA-II) | Target Info | Inhibitor | [6] | |
| KEGG Pathway | Nitrogen metabolism | |||
| Proximal tubule bicarbonate reclamation | ||||
| Collecting duct acid secretion | ||||
| Gastric acid secretion | ||||
| Pancreatic secretion | ||||
| Bile secretion | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| EGFR1 Signaling Pathway | ||||
| Pathwhiz Pathway | Gastric Acid Production | |||
| Pathway Interaction Database | C-MYB transcription factor network | |||
| Reactome | Erythrocytes take up carbon dioxide and release oxygen | |||
| Erythrocytes take up oxygen and release carbon dioxide | ||||
| Reversible hydration of carbon dioxide | ||||
| WikiPathways | Reversible Hydration of Carbon Dioxide | |||
| Uptake of Carbon Dioxide and Release of Oxygen by Erythrocytes | ||||
| Uptake of Oxygen and Release of Carbon Dioxide by Erythrocytes | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6814). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 011047. | |||
| REF 3 | The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des. 2008;14(7):649-54. | |||
| REF 4 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 5 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
| REF 6 | The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.